Department of Gastroenterology, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou 310016, Zhejiang Province, China.
Division of Gastroenterology, Loma Linda University Health, Loma Linda, CA 92354, United States.
World J Gastroenterol. 2023 Jun 14;29(22):3508-3518. doi: 10.3748/wjg.v29.i22.3508.
Although highly effective as a component of () treatment regimen, tetracycline is associated with a high incidence of medication-related adverse events. Modified dosing of tetracycline as part of quadruple therapy may improve safety while providing comparable eradication rates.
To evaluate the efficacy and safety of modified dosing of tetracycline in patients receiving tetracycline and furazolidone-containing quadruple therapy in patients with infection.
Consecutive patients (10/2020-12/2021) who received tetracycline and furazolidone quadruple therapy for infection at Sir Run Run Shaw Hospital were identified. All patients received tetracycline, furazolidone, proton pump inhibitor, and bismuth for 14 d as primary or rescue therapy. Modified tetracycline dose group received tetracycline 500 mg twice daily while standard group received 750 mg twice daily or 500 mg three times daily.
Three hundred and ninety-four patients [mean age = 46.3 ± 13.9, male = 137 (34.8%), and 309 (78.4%) primary therapy] completed tetracycline and furazolidone quadruple therapy for infection including those who received modified tetracycline dose in 157 and standard doses in 118 (750 mg twice daily) and 119 (500 mg three times daily). Eradication rates in the modified tetracycline dose group were 92.40% and in the standard groups, eradication rates were 93.20% for 750 mg twice daily group and 92.43% for 500 mg three times daily group, respectively, without statistical difference ( = 0.959). The incidence of adverse events was lower in the modified tetracycline dose (15.3% 32.3% and 29.4%; = 0.002) compared to the standard dose group.
In a real-world experience, modified tetracycline dosing as part of tetracycline and furazolidone quadruple therapy for 14 d demonstrated high efficacy, comparable to standard tetracycline dose regimens, with a favorable safety profile.
虽然作为 () 治疗方案的组成部分非常有效，但四环素与较高的药物相关不良事件发生率相关。作为四联疗法的一部分，调整四环素的剂量可能会提高安全性，同时提供相当的根除率。
评估在接受四环素和呋喃唑酮四联疗法治疗的患者中，使用四环素调整剂量治疗 感染的疗效和安全性。
连续入选 2020 年 10 月至 2021 年 12 月在浙江大学医学院附属邵逸夫医院接受四环素和呋喃唑酮四联疗法治疗的 感染患者。所有患者均接受四环素、呋喃唑酮、质子泵抑制剂和枸橼酸铋钾治疗 14 天，作为一线或补救治疗。调整剂量组接受四环素 500mg，每日 2 次，标准剂量组接受 750mg，每日 2 次或 500mg，每日 3 次。
394 例患者[平均年龄=46.3±13.9，男性=137(34.8%)，309 例(78.4%)为一线治疗]完成了四环素和呋喃唑酮四联疗法治疗 感染，其中 157 例接受调整剂量的四环素，118 例接受标准剂量的四环素[750mg，每日 2 次]和 119 例接受 500mg，每日 3 次。调整剂量组的根除率为 92.40%，标准剂量组的根除率分别为 750mg，每日 2 次组的 93.20%和 500mg，每日 3 次组的 92.43%，差异无统计学意义( = 0.959)。调整剂量组不良事件发生率较低(15.3%比标准剂量组的 32.3%和 29.4%； = 0.002)。
在真实世界经验中，作为四环素和呋喃唑酮四联疗法的一部分，调整四环素剂量治疗 14 天显示出高疗效，与标准四环素剂量方案相当，且安全性良好。
